Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy

Several clinical trials indicate that concurrent administration of tyrosine kinase inhibitors (TKIs, such as gefitinib or erlotinib) with chemotherapy agents fails to improve overall survival in advanced non-small cell lung cancer (NSCLC) patients. However, the precise mechanisms underlying the anta...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiao-Qiu, Liu, Jia-Tao, Fan, Lu-Lu, Liu, Yu, Cheng, Liang, Wang, Fang, Yu, Han-Qing, Gao, Jian, Wei, Wei, Wang, Hua, Sun, Guo-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029725/
https://www.ncbi.nlm.nih.gov/pubmed/27029054
http://dx.doi.org/10.18632/oncotarget.8358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029725/
https://www.ncbi.nlm.nih.gov/pubmed/27029054
http://dx.doi.org/10.18632/oncotarget.8358

Ejemplares similares